NWPF

News ArchivesRead News

New research program tackles Parkinson’s disease

Tuesday December 19, 2006

Jordana Lenon

December 14, 2006(University of Wisconsin System) - A new research collaboration at the University of Wisconsin-Madison aims to move promising new therapies for Parkinson’s disease from primates to patients.

Based at the Wisconsin National Primate Research Center and named the Preclinical Parkinson’s Disease Research Program, the collaboration became official in November. Joseph Kemnitz, professor of physiology and Primate Center director, is the program’s executive director. Renowned Parkinson’s disease expert Marina Emborg, senior scientist at the Primate Center and in the department of anatomy, is scientific director. "Our goal is to hasten discoveries that will lead to new therapies for Parkinson’s disease, with an emphasis on cell and gene-based therapies," says Kemnitz.

Through the new program, the Primate Center is poised to become the country’s centralized resource for Parkinson’s disease research using nonhuman primate models, especially macaques, Kemnitz says. Program collaborators and funding agencies that will help develop the necessary laboratory and animal resources at the Primate Center include WinCon, a biotechnology company in Nanning, Guangxi, China; researchers at the Beijing Institute of Geriatrics, and an anonymous foundation.

"Macaques are regarded by many as the most useful model for Parkinson’s research," Kemnitz says. "These collaborators chose the Wisconsin National Primate Research Center because we have a well established infrastructure for conducting research using nonhuman primates, and UW-Madison has a broad range of expertise directly relevant to this program."

That expertise lies in the UW-Madison’s renowned capabilities in brain imaging technology, stem cell biology and clinical biomanufacturing. Researchers from the Primate Center, Waisman Center, School of Medicine and Public Health, School of Pharmacy, and other campus entities are already developing promising Parkinson’s therapies based on embryonic stem cell derivations, trophic (nutritive) factors, compounds called thiazolidenediones, deep brain stimulation and other treatment avenues.

"We’re committed to finding a cure for Parkinson’s disease," Emborg says.

Recent News

May 30 - Smell tests, biomarkers and colon biopsies: New approaches to early identification of Parkinson’s disease
May 29 - Woman battling Parkinson's disease to try out for 'American Ninja Warrior'
May 20 - Book Review: Aging in the Key of Humor
May 19 - Press Release: The Michael J. Fox Foundation for Parkinson's Research Joins Multinational Critical Path for Parkinson's Consortium
May 19 - Congress reaches deal to overhaul chemical regulation
May 16 - Lifestyle: Why Parkinson's disease won't stop me rowing across the Pacific
May 16 - Many biomarkers for PD fail to inform on progression
May 10 - Parkinson's Cell Transplant Shows Good Reinnervation at 24 Years
May 9 - Parkinson's causes his body to freeze up. Only one thing gets him moving again.
May 7 - Growing art installation gathers stories of living with Parkinson's
May 5 - New technique can provide better cell transplants against Parkinson's disease
May 2 - What's Good For The Heart Is Good For The Brain
Apr 29 - Press Release: FDA approves first drug to treat hallucinations and delusions associated with Parkinson’s disease
Apr 28 - Dopamine-making neurons can be chemically controlled in animal model of Parkinson's
Apr 25 - Lifestyle: Dating with Disease
Apr 25 - Scientific breakthrough in fight against Parkinson's and Alzheimer's
Apr 20 - Breakthrough Parkinson's disease blood test
Apr 15 - Living with Parkinson's
Apr 12 - Tissue biomarker for dementia with Lewy bodies and Parkinson’s disease
Apr 11 - Yoga for Every Body: Experts say yoga can ease pain and improve mobility for people with neurologic conditions